tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

PHVS Stock Latest News

Pharvaris price target raised to $50 from $44 at Oppenheimer
The FlyPharvaris price target raised to $50 from $44 at Oppenheimer
23h ago
KALV
PHVS
Pharvaris price target raised to $39 from $32 at Guggenheim
PremiumThe Fly
Pharvaris price target raised to $39 from $32 at Guggenheim
23h ago
PHVS
Pharvaris’s Deucrictibant: Promising Efficacy Amidst Uncertain Market Prospects
PremiumRatings
Pharvaris’s Deucrictibant: Promising Efficacy Amidst Uncertain Market Prospects
1d ago
PHVS
Pharvaris price target raised to $30 from $27 at BofA
PremiumThe Fly
Pharvaris price target raised to $30 from $27 at BofA
1d ago
PHVS
Pharvaris price target raised to $41 from $37 at Morgan Stanley
PremiumThe Fly
Pharvaris price target raised to $41 from $37 at Morgan Stanley
1d ago
PHVS
Pharvaris’ Deucrictibant Shows Promising Efficacy and Safety in RAPIDe-3 Study, Analyst Sets Buy Rating with Increased Price Target
PremiumRatingsPharvaris’ Deucrictibant Shows Promising Efficacy and Safety in RAPIDe-3 Study, Analyst Sets Buy Rating with Increased Price Target
2d ago
PHVS
Pharvaris price target raised to $38 from $28 at Leerink
Premium
The Fly
Pharvaris price target raised to $38 from $28 at Leerink
2d ago
PHVS
Midday Fly By: Anthropic starts work on IPO, Marvell reports Q3 beat
Premium
The Fly
Midday Fly By: Anthropic starts work on IPO, Marvell reports Q3 beat
2d ago
M
W
Promising Potential of Pharvaris’s Deucrictibant in HAE Treatment Drives Buy Rating
PremiumRatings
Promising Potential of Pharvaris’s Deucrictibant in HAE Treatment Drives Buy Rating
2d ago
PHVS
Pharvaris’s IR Deucrictibant Shows Promising Phase 3 Results for HAE Treatment
PremiumRatings
Pharvaris’s IR Deucrictibant Shows Promising Phase 3 Results for HAE Treatment
2d ago
PHVS
Morning Movers: Macy’s dips following third quarter earnings report
PremiumThe Fly
Morning Movers: Macy’s dips following third quarter earnings report
2d ago
M
AEO
Pharvaris Announces Positive Results from RAPIDe-3 Study for HAE Treatment
PremiumCompany Announcements
Pharvaris Announces Positive Results from RAPIDe-3 Study for HAE Treatment
2d ago
6K
PHVS
Pharvaris’ deucrictibant meets primary endpoint in HAE attack trial
PremiumThe FlyPharvaris’ deucrictibant meets primary endpoint in HAE attack trial
2d ago
PHVS
Pharvaris Reports Q3 2025 Financial Results and Updates
Premium
Company Announcements
Pharvaris Reports Q3 2025 Financial Results and Updates
8d ago
PHVS
Pharvaris: Strong Buy Rating Backed by Promising Clinical Trials and Robust Financial Health
Premium
Ratings
Pharvaris: Strong Buy Rating Backed by Promising Clinical Trials and Robust Financial Health
17d ago
PHVS
Pharvaris price target raised to $37 from $34 at Morgan Stanley
PremiumThe Fly
Pharvaris price target raised to $37 from $34 at Morgan Stanley
21d ago
PHVS
Pharvaris Reports Q3 2025 Financial Results and Business Progress
PremiumCompany Announcements
Pharvaris Reports Q3 2025 Financial Results and Business Progress
23d ago
6K
PHVS
Promising Phase 3 Trial Data Drives Buy Rating for Deucrictibant
PremiumRatings
Promising Phase 3 Trial Data Drives Buy Rating for Deucrictibant
1M ago
PHVS
Six new option listings on October 24th
PremiumThe Fly
Six new option listings on October 24th
1M ago
SEV
DFDV
3 Best Stocks to Buy Now, 10/23/2025, According to Top Analysts
PremiumMarket News3 Best Stocks to Buy Now, 10/23/2025, According to Top Analysts
1M ago
AMZN
PHVS
Pharvaris initiated with a Buy at H.C. Wainwright
Premium
The Fly
Pharvaris initiated with a Buy at H.C. Wainwright
2M ago
PHVS
Pharvaris upgraded to Neutral from Underperform at BofA
Premium
The Fly
Pharvaris upgraded to Neutral from Underperform at BofA
2M ago
PHVS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >